Cargando…

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals

BACKGROUND: Assessing liver fibrosis is important for predicting the efficacy of direct-acting antivirals (DAAs) and patient prognosis. Non-invasive techniques to assess liver fibrosis are becoming important. Recently, serum Mac-2 binding protein glycosylation isomer (M2BPGi) was identified as a non...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saleh, Shereen A, Salama, Mohamed M, Alhusseini, Marwan M, Mohamed, Ghada A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284180/ https://www.ncbi.nlm.nih.gov/pubmed/32550761 http://dx.doi.org/10.3748/wjg.v26.i21.2864

Ejemplares similares

Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations
por: El Kassas, Mohamed, et al.
Publicado: (2020)

Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals
por: Guardigni, Viola, et al.
Publicado: (2017)

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B
por: Bui, Hoang Huu, et al.
Publicado: (2023)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection
por: Salama, Iman Ibrahim, et al.
Publicado: (2022)

Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms
por: Nardelli, Silvia, et al.
Publicado: (2019)

Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C
por: Xu, Hongqin, et al.
Publicado: (2017)

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents
por: Damiani, Giovanni, et al.
Publicado: (2018)

Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study
por: Ferrarese, Alberto, et al.
Publicado: (2018)

Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals
por: Tufan, Ayse Gokcen, et al.
Publicado: (2020)

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting
por: Chen, Jian-Hong, et al.
Publicado: (2017)

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection
por: Mak, Lung-Yi, et al.
Publicado: (2018)

Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus
por: Rupp, Christian, et al.
Publicado: (2018)

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China
por: Yang, Ying, et al.
Publicado: (2019)

The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals
por: Fayed, Hanan Mahmoud, et al.
Publicado: (2020)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis
por: Cuko, Liri, et al.
Publicado: (2022)

Novel non-invasive biological predictive index for liver fibrosis in hepatitis C virus genotype 4 patients
por: Khattab, Mahmoud, et al.
Publicado: (2016)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
por: Abu-Freha, Naim, et al.
Publicado: (2023)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Hepatitis C Virus-associated Membranoproliferative Glomerulonephritis Treated with Directly Acting Antiviral Therapy
por: Nayak, S., et al.
Publicado: (2018)

Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma
por: Ismail, Mohamed Saleh, et al.
Publicado: (2021)

IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy
por: Attallah, Abdelfattah M., et al.
Publicado: (2021)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population
por: Kim, Mimi, et al.
Publicado: (2020)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals
por: Nguyen, Kelvin, et al.
Publicado: (2017)

Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals
por: Alswat, Khalid, et al.
Publicado: (2022)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
por: Niu, Bin, et al.
Publicado: (2023)

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis
por: Wellington, Jennifer, et al.
Publicado: (2021)

Diagnostic performance of Mac‐2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups
por: Nah, Eun‐Hee, et al.
Publicado: (2020)

Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
por: Takemura, Kazuya, et al.
Publicado: (2020)

Genistein Targets STING-Driven Antiviral Responses
por: Ullah, Tomalika R., et al.
Publicado: (2022)

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review
por: El Kassas, Mohamed, et al.
Publicado: (2019)

Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi
por: Baudi, Ian, et al.
Publicado: (2020)

Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma
por: Ismail, Mohamed Saleh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eclo2bktj2jqqs12kgslaljo2h